Cargando…

Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity

The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransfera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuegg, Johannes, Muldoon, Craig, Adamson, George, McKeveney, Declan, Le Thanh, Giang, Premraj, Rajaratnam, Becker, Bernd, Cheng, Mu, Elliott, Alysha G., Huang, Johnny X., Butler, Mark S., Bajaj, Megha, Seifert, Joachim, Singh, Latika, Galley, Nicola F., Roper, David I., Lloyd, Adrian J., Dowson, Christopher G., Cheng, Ting-Jen, Cheng, Wei-Chieh, Demon, Dieter, Meyer, Evelyne, Meutermans, Wim, Cooper, Matthew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530474/
https://www.ncbi.nlm.nih.gov/pubmed/26194781
http://dx.doi.org/10.1038/ncomms8719
_version_ 1782384906286923776
author Zuegg, Johannes
Muldoon, Craig
Adamson, George
McKeveney, Declan
Le Thanh, Giang
Premraj, Rajaratnam
Becker, Bernd
Cheng, Mu
Elliott, Alysha G.
Huang, Johnny X.
Butler, Mark S.
Bajaj, Megha
Seifert, Joachim
Singh, Latika
Galley, Nicola F.
Roper, David I.
Lloyd, Adrian J.
Dowson, Christopher G.
Cheng, Ting-Jen
Cheng, Wei-Chieh
Demon, Dieter
Meyer, Evelyne
Meutermans, Wim
Cooper, Matthew A.
author_facet Zuegg, Johannes
Muldoon, Craig
Adamson, George
McKeveney, Declan
Le Thanh, Giang
Premraj, Rajaratnam
Becker, Bernd
Cheng, Mu
Elliott, Alysha G.
Huang, Johnny X.
Butler, Mark S.
Bajaj, Megha
Seifert, Joachim
Singh, Latika
Galley, Nicola F.
Roper, David I.
Lloyd, Adrian J.
Dowson, Christopher G.
Cheng, Ting-Jen
Cheng, Wei-Chieh
Demon, Dieter
Meyer, Evelyne
Meutermans, Wim
Cooper, Matthew A.
author_sort Zuegg, Johannes
collection PubMed
description The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransferases, which are essential for peptidoglycan polymerization, while displaying a low rate of resistance. Unfortunately, the lipophilicity of moenomycin leads to unfavourable pharmacokinetic properties that render it unsuitable for systemic administration. In this study, we show that using moenomycin and other glycosyltransferase inhibitors as templates, we were able to synthesize compound libraries based on novel pyranose scaffold chemistry, with moenomycin-like activity, but with improved drug-like properties. The novel compounds exhibit in vitro inhibition comparable to moenomycin, with low toxicity and good efficacy in several in vivo models of infection. This approach based on non-planar carbohydrate scaffolds provides a new opportunity to develop new antibiotics with low propensity for resistance induction.
format Online
Article
Text
id pubmed-4530474
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Pub. Group
record_format MEDLINE/PubMed
spelling pubmed-45304742015-08-11 Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity Zuegg, Johannes Muldoon, Craig Adamson, George McKeveney, Declan Le Thanh, Giang Premraj, Rajaratnam Becker, Bernd Cheng, Mu Elliott, Alysha G. Huang, Johnny X. Butler, Mark S. Bajaj, Megha Seifert, Joachim Singh, Latika Galley, Nicola F. Roper, David I. Lloyd, Adrian J. Dowson, Christopher G. Cheng, Ting-Jen Cheng, Wei-Chieh Demon, Dieter Meyer, Evelyne Meutermans, Wim Cooper, Matthew A. Nat Commun Article The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransferases, which are essential for peptidoglycan polymerization, while displaying a low rate of resistance. Unfortunately, the lipophilicity of moenomycin leads to unfavourable pharmacokinetic properties that render it unsuitable for systemic administration. In this study, we show that using moenomycin and other glycosyltransferase inhibitors as templates, we were able to synthesize compound libraries based on novel pyranose scaffold chemistry, with moenomycin-like activity, but with improved drug-like properties. The novel compounds exhibit in vitro inhibition comparable to moenomycin, with low toxicity and good efficacy in several in vivo models of infection. This approach based on non-planar carbohydrate scaffolds provides a new opportunity to develop new antibiotics with low propensity for resistance induction. Nature Pub. Group 2015-07-21 /pmc/articles/PMC4530474/ /pubmed/26194781 http://dx.doi.org/10.1038/ncomms8719 Text en Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Zuegg, Johannes
Muldoon, Craig
Adamson, George
McKeveney, Declan
Le Thanh, Giang
Premraj, Rajaratnam
Becker, Bernd
Cheng, Mu
Elliott, Alysha G.
Huang, Johnny X.
Butler, Mark S.
Bajaj, Megha
Seifert, Joachim
Singh, Latika
Galley, Nicola F.
Roper, David I.
Lloyd, Adrian J.
Dowson, Christopher G.
Cheng, Ting-Jen
Cheng, Wei-Chieh
Demon, Dieter
Meyer, Evelyne
Meutermans, Wim
Cooper, Matthew A.
Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
title Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
title_full Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
title_fullStr Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
title_full_unstemmed Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
title_short Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
title_sort carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530474/
https://www.ncbi.nlm.nih.gov/pubmed/26194781
http://dx.doi.org/10.1038/ncomms8719
work_keys_str_mv AT zueggjohannes carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT muldooncraig carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT adamsongeorge carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT mckeveneydeclan carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT lethanhgiang carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT premrajrajaratnam carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT beckerbernd carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT chengmu carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT elliottalyshag carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT huangjohnnyx carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT butlermarks carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT bajajmegha carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT seifertjoachim carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT singhlatika carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT galleynicolaf carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT roperdavidi carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT lloydadrianj carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT dowsonchristopherg carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT chengtingjen carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT chengweichieh carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT demondieter carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT meyerevelyne carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT meutermanswim carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity
AT coopermatthewa carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity